<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963129</url>
  </required_header>
  <id_info>
    <org_study_id>2666</org_study_id>
    <nct_id>NCT02963129</nct_id>
  </id_info>
  <brief_title>Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT</brief_title>
  <official_title>Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients
      with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary hemorrhagic telangiectasia is a vascular dysplasia characterized by the
      development of mucocutaneous telangiectasia and arteriovenous malformations in organs such as
      brain, lung, liver and tube digestivo. Is considered a rare disease, although It means that
      there is a substantial underdiagnosis. The overall prevalence is 1/5000.

      Approximately 60% of the general population hosts strains of Staphylococcus aureus (S.
      aureus) intermittently and are called intermittent carriers, 20% represent persistent
      carriers harboring the same strain of S. aureus and 20% of the population are never carriers.

      On this concept, one might think that HHT patients in whom there is an active and
      pathological vascular remodeling that causes bleeding, and inflammation is a known activator
      of abnormal angiogenesis; reducing an inflammatory factor as microbial through the
      eradication of nasal S. aureus could be useful to reduce bleeding in this population,
      directly impacting on quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2017</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nosebleed by sadick scale</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of nasal colonization with Staphylococcus in patients with HHT by nasal cultive</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hereditary Hemorrhagic Telangiectasia</condition>
  <condition>Epistaxis</condition>
  <arm_group>
    <arm_group_label>Mupirocina</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin</intervention_name>
    <description>Mupirocin ointment in the nose for 5 days</description>
    <arm_group_label>Mupirocina</arm_group_label>
    <other_name>Mupirocina 2% ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo ointment in the nose for 5 days</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>ointment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years with possible or confirmed HHT as diagnostic criteria Cura√ßao.

          -  Patients with nasal S. aureus colonization culture positive

        Exclusion Criteria:

          -  Refusal to participate in the study or the informed consent process.

          -  Hypersensitivity or contraindication for topical mupirocin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo MS Serra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staff of the Department of Clinical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo MS Serra, MD</last_name>
    <phone>49590200</phone>
    <phone_ext>4806</phone_ext>
    <email>marcelo.serra@hospitalitalino.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina CE Elizondo, MD</last_name>
    <phone>49590200</phone>
    <phone_ext>4806</phone_ext>
    <email>cristina.elizondo@hospitalitalino.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires, Peron 4190</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires, Gascon 450</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Hemorrhagic Telangiectasia</keyword>
  <keyword>Epistaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Epistaxis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

